This Phase 1/Phase 2 study will evaluate GMI-1070, a pan-selectin inhibitor, in adults with stable sickle cell disease. The study will assess safety, pharmacokinetics, and microvascular effects of intravenous GMI-1070 in the outpatient setting.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
15
Intravenous GMI-1070 given as two doses over the course of one day
Children's Hospital & Research Center Oakland
Oakland, California, United States
University of California at Davis, CCRC
Sacramento, California, United States
Duke Comprehensive Sickle Cell Center
Durham, North Carolina, United States
Safety as Measured by the Number of Participants With Adverse Events
Time frame: 28 days
Total Plasma Clearance
Time frame: 48 hours
Volume of the Central Compartment
Time frame: 48 hours
Intercompartmental Clearance
Time frame: 48 hours
Volume of the Peripheral Compartment
Time frame: 48 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.